【摘 要】
:
Background: Treatment for Chronic Myeloid Leukaemia (CML) is mainly imatinib mesylate (IM) from original-brand, Glivec? or generic-type homologs, Imatib?. Mater
【机 构】
:
DepartmentofBiochemistry,DepartmentofHaematology,DepartmentofHaematology,DepartmentofImmunologyandMi